Loading
This large sequencing study defined MET exon 14 skipping as a recurrent driver in about 3 percent of lung adenocarcinomas and other cancers, showed the mutations are diverse and easily missed, and reported patients responding to MET inhibitors.
Analysis of comprehensive genomic profiling from more than 38,000 tumours identifying MET exon 14 splice-site alterations in about 3 percent of lung adenocarcinomas and at lower frequency in other tumours, characterising the wide range of DNA changes involved, and describing responses to crizotinib and capmatinib in patients harbouring them.
The paper established MET exon 14 skipping as a bona fide lung cancer driver and showed why RNA-based or broad DNA testing is needed to detect it, paving the way for capmatinib and tepotinib.
Shares MET exon 14 skipping mutation, MET exon 14 skipping mutation, Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Receptor tyrosine kinase activation.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Non-small-cell lung cancer.
Shares MET exon 14 skipping mutation, MET exon 14 skipping mutation, Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares MET exon 14 skipping mutation, MET exon 14 skipping mutation, MET, Receptor tyrosine kinase activation.
Shares Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Non-small-cell lung cancer.
Shares MET exon 14 skipping mutation, MET, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Non-small-cell lung cancer.